Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du Sells 23,669 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 23,669 shares of the business’s stock in a transaction on Thursday, June 26th. The shares were sold at an average price of $36.13, for a total transaction of $855,160.97. Following the completion of the transaction, the chief executive officer now owns 514,982 shares of the company’s stock, valued at approximately $18,606,299.66. This represents a 4.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ying Du also recently made the following trade(s):

• On Tuesday, May 13th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $28.57, for a total transaction of $1,428,500.00.
• On Wednesday, May 14th, Ying Du sold 46,389 shares of Zai Lab stock. The stock was sold at an average price of $28.09, for a total transaction of $1,303,067.01.
• On Friday, April 4th, Ying Du sold 2,945 shares of Zai Lab stock. The stock was sold at an average price of $33.11, for a total value of $97,508.95.
• On Wednesday, April 2nd, Ying Du sold 5,808 shares of Zai Lab stock. The shares were sold at an average price of $35.89, for a total value of $208,449.12.

Zai Lab Stock Performance

Shares of ZLAB opened at $34.74 on Friday. The stock has a 50 day moving average price of $33.46 and a 200 day moving average price of $31.07. Zai Lab Limited Unsponsored ADR has a one year low of $16.01 and a one year high of $44.34. The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of -13.95 and a beta of 0.96.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05. The business had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. On average, analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Institutional Trading of Zai Lab

Several large investors have recently bought and sold shares of the business. US Bancorp DE lifted its stake in Zai Lab by 1,671.9% in the 4th quarter. US Bancorp DE now owns 5,865 shares of the company’s stock worth $154,000 after purchasing an additional 5,534 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Zai Lab during the fourth quarter worth approximately $1,032,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Zai Lab during the fourth quarter worth $1,674,000. Daiwa Securities Group Inc. boosted its stake in Zai Lab by 44.7% during the fourth quarter. Daiwa Securities Group Inc. now owns 13,833 shares of the company’s stock worth $362,000 after buying an additional 4,276 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Zai Lab by 39.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 841,735 shares of the company’s stock valued at $22,045,000 after buying an additional 237,582 shares in the last quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ZLAB shares. JPMorgan Chase & Co. upped their target price on Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, March 13th. Scotiabank began coverage on shares of Zai Lab in a research report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a report on Thursday, March 27th. Bank of America reissued a “neutral” rating and set a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Finally, Wall Street Zen downgraded shares of Zai Lab from a “buy” rating to a “hold” rating in a research report on Friday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $47.37.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.